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costs in relation to zolendronate per QALYs and SRE free-years
produced, zolendronate was dominated by clodronate. Multi-
variate sensibility analysis did not show changes in the initial
results of this pharmacoeconomic model CONCLUSIONS: From
the Brazilian Ministry of Health perspective, clodronate was
dominant in comparison to zoledronate in preventing SREs in
patients with BM.
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OBJECTIVES: Treatment options for patients with relapsed mul-
tiple myeloma (MM) have recently seen the addition of a number
of new therapies. Some of these may be used in combination, but
there is no clear standard of care and the relative cost-
effectiveness of the new therapies or combinations thereof
remains largely untested. Pegylated liposomal doxorubicin in
combination with botrezomib represents a new alternative whose
clinical performance appears to give better patient outcomes
(both overall survival (OS) and progression-free survival (PFS)
than bortezomib alone. To complete a technology appraisal
within the Scottish health care setting, a cost-effectiveness model
was developed comparing the combination therapy against bort-
ezomib monotherapy as well as against high-dose dexametha-
sone monotherapy. METHODS: The model used clinical
outcomes data from the licensing trials of the combination
therapy (DOXIL MMY-301 study) as well as the licensing trial
for bortezomib monotherapy (APEX study). Patient utilities
prior to and after progression were sourced from a published
cost-effectiveness study. A ten-year timeframe was assumed and
available clinical data for PFS and OS were extended using
Weibull regression methods. RESULTS: The results from our
base case analysis suggest that the combination therapy is cost-
effective compared to bortezomib monotherapy (ICER £17,303/
QALY) as well as versus high-dose dexamethasone therapy
(ICER £27,880/QALY). Incorporation of further clinical OS and
PFS statistics from a recent data update resulted in a slight
increase in ICERs, however these remained cost-effective. CON-
CLUSIONS: The model suggests that the combination therapy
would be a cost-effective addition to the Scottish treatment
paradigm.
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OBJECTIVES: Trastuzumab is a humanized monoclonal anti-
body against the extracellular domain of HER-2 and it has
activity in early and advanced breast cancer with HER-2 over-
expression. The cost-effectiveness of trastuzumab in 1 year
therapy was assessed for patients with breast cancer who had
completed loco-regional surgery and at least four cycles of neo-
adjuvant or adjuvant chemotherapy in comparison with obser-
vation from the public health care system perspective.
METHODS: This cost-effectiveness analysis was based on the
HERA trial. A modiﬁed Delphi panel with local specialists was
conducted to identify local resources usage for treating breast
cancer. Costing was based on public sources. A 5-state Markov
model was developed to simulate the disease progression:
disease-free survival, recurrence, metastatic, cardiac events and
death. Only direct costs were considered in the calculation and a
lifetime perspective was assumed. A discounting rate of 5% was
adopted according to DECIT local guidelines for economic
evaluation. Probabilistic sensitivity analysis was performed to
account the robustness of the estimates. RESULTS: Trastuzumab
treatment costs were higher than those of the observational arm:
a R$ 43,363 increment for trastuzumab. The use of trastuzumab
reduced time in the metastatic state by 1.15 years and then
cost-offsets of R$67,472 were observed as a consequence. For the
total period, trastuzumab arm presented an increase in dis-
counted overall survival of 1.36 life years and a discounted
quality-adjusted survival of 1.44 QALYs, and also a favorable
ICER of R$30,040 per QALY. CONCLUSIONS: This cost-
effectiveness analysis suggests that the use of trastuzumab in
adjuvant therapy for patients with early breast cancer HER-2
positive brings important clinical beneﬁts to the patients and in
addition is a cost-effective alternative within the Brazilian public
health care system perspective.
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OBJECTIVES: The purpose of this analysis was to examine the
economic efﬁciency of treating metastatic colorectal cancer
(mCRC) with XELOX +/- Bevacizumab every three weeks versus
FOLFOX-4 +/– Bevacizumab every two weeks as ﬁrst-line treat-
ment. METHODS: The decision model was developed from the
social perspective. The mean annual total cost per patient treated
was estimated considering the annual drug costs, the annual cost
associated with the drug administration and the annual cost to
treat the adverse effects induced by each regime. We include the
social costs derived from the time that the patient incurred in the
chemotherapy administration process and the time consumed by
travelling to the health care centre. According to the trial, the
treatments with XELOX and FOLFOX-4 have a similar effec-
tiveness proﬁles. RESULTS: Total direct annual cost from the
perspective of the health care payer was €639 inferior with
XELOX when compared with FOLFOX-4 and €1887 inferior
when it was compared [XELOX + Bevacizumab] with
[FOLFOX-4 + Bevacizumab]. Including indirect costs, the
regimes with XELOX presented a lower cost of €1534 (without
bevacizumab) and €3.003 (with bevacizumab) when they are
compared with the respective regimes with FOLFOX-4. CON-
CLUSIONS: The smaller annual cost of the chemotherapy based
on XELOX it is due to a relatively smaller costs associated to the
administration of oral capecitabine; the implantation of a central
venous access device which is not needed in the great majority of
patients following the XELOX regimes; and for the smaller
number of administration cycles throughout the 48 weeks period
under study.
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